SUCCESS IN THE DETAILS – SALES AND MARKETING.  Allergan’s innovative eye care products are available in more than 100 countries, making us one of the world’s leading manufacturers of ophthalmic pharmaceuticals. Our products are detailed to physicians by the largest pharmaceutical sales force in the world (excluding Japan) ded- icated to only ophthalmology. As part of our ongoing effort to provide excellent service to physicians, Allergan invests considerably in the recruiting and hiring of its sales organization and in sales force training and development. In an independent survey conducted by Verispan, ophthalmologists ranked the Allergan sales force No. 1 in the United States in terms of overall performance – for the sixth year in a row. outlook: from the cornea to the optic nerve Allergan’s historical growth has been driven by a combina- tion of strong sales and marketing capabilities and pioneering products, with particular success achieved in the fields of glaucoma and dry eye. Moving forward, we are focused on innovative approaches to treat retinal diseases, the largest unmet eye care need in developed countries. As part of that quest, we acquired Oculex Pharmaceuticals, Inc., a privately held company developing therapeutic prod- ucts for the treatment of retinal diseases. We believe that Oculex's proprietary, bioerodable sustained-release implant will be a world-class method to deliver innovative, sight- saving pharmaceuticals to the back of the eye. Back-of-the-eye disorders include age-related macular degeneration, diabetic retinopathy and macular edema. With the Oculex acquisition came POSURDEX, a drug delivery system that releases a well understood steroid called dexamethasone in the eye’s vitreous – the space behind the lens of the eye.  A 306-patient Phase II study has shown that POSURDEX was significantly better than observation in treating macular edema, a swelling of the retina. Macular edema is associ- ated with a number of retinal diseases, including diabetic retinopathy, and is a common cause of vision loss in patients with retinal disease. In fact, it affects up to 750,000 patients in the United States alone. We will initiate Phase III trials for POSURDEX in 2004.  Our strategic goal is to leverage the Oculex platform  to deliver Allergan’s proprietary, innovative compounds to treat retinal disease. ophthalmology Besides being extremely small, the implants used in the POSURDEX delivery  system bioerode for sustained drug release.